Annual Review

U-M Tech Transfer generated a record number of spinouts for a second consecutive year but reported less funding for its portfolio.

The TTO reported decreased spinout generation, licensing revenue and funding however marked a notable exit in the sale of Tissue Analytics.

Inserm's tech transfer office generated a $60.4m turnover during 2019, the year that saw Pfizer acquire its biotech spinout Therachon for at least $340m.

There was a record number of first-time corporate investors in the first half of the year despite corporate venturing activity being down across deals, exits and funds.

Cambridge Innovation Capital has released its annual results, celebrating a 46% increase in net asset value and its first IPO exit.

GUV’s annual review shows the ecosystem is in outstanding shape despite of all the doom and gloom in many financial papers.

Countries like Germany, Switzerland and Japan have benefitted from an explosive growth in capital, but the US still dominates and the UK risks being left behind, our in-depth analysis shows.

Just 249 investments were announced in the last three months of 2022 but the year was still the second-best on record in almost every category.

Amid a general downturn, spinouts have been faring much better than the startup world at large.

Despite being the first year spent entirely during the pandemic, 2021 underlined the strengths of the ecosystem with spinouts raising nearly $39.2bn.